Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Gilead’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the reins ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Notable insider trades include Parsey Merdad, Chief Medical Officer at Gilead Sciences, Inc. (GILD), who sold 21246 shares on Sep 12 ’24, at $84.5 each, totaling $1.80 million. On Sep 12 ’24, Mercier ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc (NASDAQ:GILD), sold 29,357 shares of the company on ...

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...